Pilot Projects Program

试点项目计划

• 批准号: 10684635
• 负责人: Curtis William Noonan
• 金额: $ 149.17万
• 依托单位: UNIVERSITY OF NEVADA LAS VEGAS
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-15 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10684635
• 关键词: Acceleration; Address; Award; Basic Science; Biometry; Centers of Research Excellence; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Communities; Community Outreach; Complex; Development; Extramural Activities; Faculty; Fostering; Funding; Funding Mechanisms; Goals; Grant; Health; Health Disparities Research; Infrastructure; Institution; Investments; Leadership; Mentors; Mentorship; Modeling; Multi-Institutional Clinical Trial; Network Infrastructure; Outcome; Patients; Pilot Projects; Population; Populations at Risk; Program Development; Research; Research Activity; Research Personnel; Resources; Site; Testing; Translational Research; Work; career; clinical research site; cohort; community engagement; experience; health disparity; innovation; multidisciplinary; pre-clinical; pre-clinical research; programs; success; support network

Summary The Clinical and Translational Infrastructure Network (CTR-IN) is a partnership of 13 institutions across 7 states to develop a culture of collaborative multidisciplinary clinical and translational health disparities research within and across western IDeA institutions to positively impact health in our communities. Support for CTR pilot projects is one of the key CTR-IN activities. The CTR-IN Pilot Projects Program (CP3, formerly known as CTPG [Clinical and Translational Pilot Grants]) has developed well-tested strategies for solicitation, merit review, and oversight of pilot grants. The success of CTR-IN pilot awardees is made possible through the close integration of CP3 funding for investigators with the biostatistical, mentorship and professional development support from the complementary CTR-IN Cores. To further grow the successful CP3, we have evolved our strategy to focus on health disparities research, and we have developed innovative strategies to support multisite collaborations and the building of multidisciplinary CTR teams. The CP3 funding strategies will enhance current CTR capacity in the region on several fronts. First, over the past 5 years a high proportion of investigators with CTR-IN pilot grant support have successfully obtained competitive extramural funding, yielding a positive return on investment that will continue to grow. We will continue to advance this objective by working in close collaboration with the new Community Engagement and Outreach (CEO) Core to identify populations at risk and health disparities of concern in our communities. Second, partnering across sites will build the necessary infrastructure to compete nationally for multisite clinical trials and related research. Our recent support of multisite collaborative pilot projects demonstrates both the demand for such projects among researchers and the proof of concept for initiating these more complex projects. Finally, supporting partnerships that bridge preclinical and clinical research will accelerate the delivery of solutions to patients and communities. Faculty at our partner institutions include a broad cohort of IDeA-supported basic science, preclinical investigators (e.g., INBRE, COBRE) and clinical investigators, yielding opportunities for building teams and leveraging core resources to advance research for greater benefit to patients and communities. Altogether, these strategies and anticipated outcomes will have an important impact on health in our communities.

概括 临床和转化基础设施网络 (CTR-IN) 是 7 个州 13 家机构的合作伙伴 在内部发展协作多学科临床和转化健康差异研究的文化 以及整个西方 IDeA 机构，以积极影响我们社区的健康。支持 CTR 试点 项目是 CTR-IN 的关键活动之一。 CTR-IN 试点项目计划（CP3，以前称为 CTPG [临床和转化试点补助金]) 制定了经过充分测试的策略，用于征集、绩效审查和 对试点补助金的监督。 CTR-IN 试点获奖者的成功得益于紧密的整合 为研究人员提供 CP3 资金，并提供生物统计、指导和专业发展支持 互补的 CTR-IN 核心。为了进一步发展成功的 CP3，我们制定了战略，重点关注 关于健康差异研究，我们制定了创新战略来支持多地点合作 以及多学科CTR团队的建设。 CP3 资助策略将增强当前的 CTR 能力 在该地区的几个方面。首先，过去5年CTR-IN试点的研究者比例很高 赠款支持已成功获得有竞争力的校外资金，产生积极的投资回报 这将继续增长。我们将继续与各方密切合作，推进这一目标 新的社区参与和外展 (CEO) 核心，用于识别高危人群和健康差异 我们社区的担忧。其次，跨站点合作将建立必要的基础设施来竞争 全国范围内进行多中心临床试验和相关研究。我们最近对多站点协作试点的支持 项目既表明了研究人员对此类项目的需求，也证明了概念的验证 启动这些更复杂的项目。最后，支持连接临床前和临床的合作伙伴关系 研究将加速向患者和社区提供解决方案。我们合作机构的教师 包括 IDeA 支持的广泛的基础科学、临床前研究人员（例如 INBRE、COBRE）和 临床研究人员，为建立团队和利用核心资源推进提供机会 为患者和社区带来更大利益的研究。总而言之，这些策略和预期结果 将对我们社区的健康产生重要影响。